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Introduction
Takayasu arteritis (TA) is a chronic systemic granulo-
matous vasculitis of large vessels. Corticosteroids may
induce remission. However, over half of patients flare
with tapering of corticosteroids. There are anecdotal
reports of treatment with methotrexate, azathioprine,
and biologics such as infliximab. Cyclophosphamide is
recommended for life-threatening or organ-threatening
patients. However, patients, especially with HLA B52-
positive, are frequently refractory to these treatments.
Since serum levels of interleukin (IL)-6 are correlated
with disease activity, an open-label trial of tocilizumab
(TCZ), an anti-IL-6 receptor monoclonal antibody, was
conducted for 6 pediatric patients with TA.
Objectives
To assess the efficacy and safety of TCZ for patients
with TA refractory to conventional treatments.
Methods
Six patients with TA were eligible in this study. Diagnosis
of TA was made by clinical manifestations, blood exami-
nations and imaging assessments. TCZ (8-10 mg/kg) was
intravenously administered in 6 patients with TA every 2
weeks. The efficacy and tolerability of TCZ were evaluated
by TA disease activity, laboratory findings, and corticoster-
oid reductions at 6, 12 and 24 months after TCZ initiation.
Ultrasound, [18F]-FDG-PET, PET/CT, and MRI angiogram
were performed before and after TCZ treatment.
Results
The median onset age was 12.5 years (range; 7-17 years)
and the median disease duration was 94 months (range;
18-192 months). Among 6 patients with TA, there was
1 patient complicated with ulcerative colitis, 1 patient
with heart failure, and 1 patient with brain ischemia.
HLA-B52 was positive in 4 out of 6 patients. The pre-
vious treatments, which were judged as ineffective or
had side effects, were corticosteroids (6/6), intravenous
cyclophosphamide (5/6), azathioprine (3/6), mycopheno-
late mofetil (2/6), methotrexate (2/6) and infliximab (2/
6). The mean duration of TCZ treatment was 24
months (range to 6-58 months). Before starting TCZ,
patients had clinical symptoms of fever (2/6), myalgia
(4/6), headache (4/6), hypertension (2/6) and abdominal
pain (1/6). All of these symptoms were improved during
TCZ therapy. The mean erythrocyte sedimentation rate
was 36.1 mm/hour (range 11-58 mm/hour) before TCZ,
and it decreased to 3.2 mm/hour (range 1-6 mm/hour)
6 months after TCZ. The mean doses of prednisolone
were 24.3 mg/day (range 11-45 mg/day) before TCZ,
and they decreased to 18.0 mg/day (range 11-40 mg/
day), 14.1 mg/day (range 10-22.5 mg/day), and 5.7 mg/
day (range 5-6.5 mg/day) in 6, 12 and 24 months,
respectively, after starting TCZ. Although serum IL-6
levels increased in 2-3 months after the initial TCZ
administration with the mean level of 198.8 pg/ml
(range 20.7-548.1 pg/ml), they gradually decreased to
33.3 pg/ml (range 7.1-54.8 pg/ml) within 6 months.
MRI angiogram findings were improved in 3/6 cases 6
months to 2 years after TCZ therapy. No serious
adverse events were observed.
Conclusion
TCZ was effective and well tolerated for patients
with TA refractory to corticosteroids and various
immunosupressants.
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